Haha I'll have some of what you're smoking!
Both companies are developing a drug, of course.
ARG-007 has been shown to be safe and stable when given alongside a thrombolytic. Of course they would still give a thrombolytic for ischaemic stroke - what, you suggest leaving the blood clot there!?
If NYR ever trial our drug in ishaemic stroke, they will also need to show that it can be given with a thrombolytic.
I don't know how you could claim NYR has a more effective drug - clearly you have no grasp of science or statistics. We could only know when both complete clinical trials in the same indication.
I think the main reasons for NYRs low MC were the continued delays in reaching pre-clinical milestones, followed by the shock failure of their lead cholesterol-lowering candidate to pass toxicology studies. Makes sense that investors hae been wary since.
- Forums
- ASX - By Stock
- Ann: Nyrada Commences Walter Reed Traumatic Brain Injury Study
Haha I'll have some of what you're smoking! Both...
- There are more pages in this discussion • 168 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NYR (ASX) to my watchlist
|
|||||
Last
6.6¢ |
Change
0.003(4.76%) |
Mkt cap ! $12.02M |
Open | High | Low | Value | Volume |
6.3¢ | 6.6¢ | 5.7¢ | $66.11K | 1.090M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 101030 | 6.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.6¢ | 205 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.060 |
1 | 172430 | 0.058 |
3 | 78015 | 0.057 |
2 | 19357 | 0.056 |
3 | 51674 | 0.055 |
Price($) | Vol. | No. |
---|---|---|
0.066 | 205 | 1 |
0.069 | 33333 | 1 |
0.070 | 51535 | 3 |
0.071 | 100000 | 1 |
0.072 | 10000 | 1 |
Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
Last
6.3¢ |
  |
Change
0.003 ( 1.56 %) |
|||
Open | High | Low | Volume | ||
6.3¢ | 6.8¢ | 5.7¢ | 547089 | ||
Last updated 15.38pm 14/06/2024 ? |
Featured News
NYR (ASX) Chart |